Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $47.40 and last traded at $46.93, with a volume of 49561 shares changing hands. The stock had previously closed at $44.30.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $55.00.
Read Our Latest Research Report on Metsera
Metsera Stock Down 6.6%
The firm has a 50 day moving average of $30.49.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Alphabet Inc. purchased a new position in shares of Metsera during the first quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. bought a new stake in Metsera in the first quarter worth $78,748,000. Wellington Management Group LLP bought a new position in Metsera in the 1st quarter valued at approximately $65,382,000. Alpha Wave Global LP purchased a new stake in Metsera during the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in Metsera during the 1st quarter valued at $42,395,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access